fda 503a bulks list bpc-157 category 2 An advisory committee voted Thursday to remove compounding restrictions on four peptides despite little evidence the products are safe or effective for medical use. In a series of 8-6 votes (with Exciting news for peptides coming

Exciting news for peptides coming out of today's committee hearing! The FDA Pharmacy Compounding Advisory Committee voted 8 6 to recommend adding BPC 157 to the 503A Bulks List for use in compounding for The Precision Peptide Company Applauds FDA Advisory Committee Vote on Expanded Pathway for BPC 157 and KPV FDA Pharmacy Compounding Committee Votes on Peptide Policy John Hoekman posted on the topic LinkedIn BREAKING: The FDA just reversed theIR 2023 peptide ban. 12 peptides were just pulled from the Category 2 restricted list: 1. BPC 157 2. Thymosin beta 4 fragment (TB 500) 3. Epitalon 4. GHK Cu (injectable)

SKU: 74290583516 · From iglepidom.org